Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp or placebo daily for seven days. Following assessment of safety and PK data of each successive cohort, ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation sensor as 50% smaller than the G7, with a thinner, lower-circumference form ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic ...

Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...